Treatment of heart failure with preserved ejection fraction

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a major public health problem in the United States. However, in contrast to systolic heart failure, there are little data to guide treatment decisions in HFpEF, and no therapies have been shown to improve outcome in these patients. This review explores what is currently known about the pathophysiologic mechanisms causing HFpEF in order to frame appropriate therapeutic targets and better understand the clinical responses commonly observed in patients with HFpEF. Data from published clinical trials are reviewed, and the roles for each class of drug commonly used in practice are examined. Finally, novel therapies and future directions for basic investigation and clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this